Phase 1 Retinitis Pigmentosa Clinical Trials
14 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–14 of 14 trials
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
Retinitis Pigmentosa
Sumitomo Pharma America, Inc.12 enrolled2 locationsNCT06891885
Recruiting
Phase 1Phase 2
A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
Retinitis Pigmentosa
Octant, Inc.50 enrolled1 locationNCT07408232
Recruiting
Phase 1Phase 2
BS01 in Patients With Retinitis Pigmentosa
Retinitis Pigmentosa
Bionic Sight LLC20 enrolled1 locationNCT04278131
Recruiting
Phase 1Phase 2
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
Retinal DegenerationRetinal DiseaseRetinal Dystrophies+2 more
PYC Therapeutics16 enrolled6 locationsNCT06852963
Recruiting
Phase 1Phase 2
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)
Retinitis PigmentosaChoroideremiaNon-Syndromic Rod-Dominant Inherited Retinal Diseases
Kiora Pharmaceuticals, Inc.48 enrolled3 locationsNCT05282953
Recruiting
Phase 1
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
Age-Related Macular DegenerationAlcohol Use DisorderRetinitis Pigmentosa+2 more
University of Rochester15 enrolled1 locationNCT06319872
Recruiting
Phase 1Phase 2
Promising ROd-cone DYstrophy Gene therapY
Retinitis Pigmentosa
SparingVision33 enrolled6 locationsNCT05748873
Recruiting
Phase 1Phase 2
Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis Pigmentosa
Retinitis Pigmentosa
Mahidol University15 enrolled1 locationNCT06242379
Recruiting
Phase 1
An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa
Retinitis Pigmentosa
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine21 enrolled1 locationNCT06936787
Recruiting
Phase 1
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION
Retinitis PigmentosaMacular DegenerationDiabetic Retinopathy+3 more
The Foundation for Orthopaedics and Regenerative Medicine20 enrolled2 locationsNCT05147701
Recruiting
Phase 1
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
Retinitis Pigmentosa
VeonGen Therapeutics GmbH6 enrolled1 locationNCT06291935
Recruiting
Phase 1
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
Retinal DegenerationRetinal DiseaseEye Diseases+2 more
PYC Therapeutics12 enrolled5 locationsNCT06455826
Recruiting
Phase 1Phase 2
Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa
X-Linked Retinitis Pigmentosa (XLRP)
Frontera Therapeutics32 enrolled1 locationNCT06492850
Completed
Phase 1
A study of a new drug, NPI-001 in healthy volunteers to test its safety and tolerability
Retinitis pigmentosa (RP)
Nacuity Pharmaceuticals Pty Ltd54 enrolled1 locationACTRN12617000911392